公开(公告)号：US11472879B2

公开(公告)日：2022-10-18

申请号：US16778523

申请日：2020-01-31

Applicant: UCB Biopharma SRL

Inventor： Helene Margaret Finney ,  Stephen Edward Rapecki ,  Kerry Louise Tyson ,  Michael John Wright

IPC: C07K16/28 ,  A01K67/027 ,  A61K39/00

Abstract: The present disclosure relates to antibody molecules comprising a binding domain specific to CD22, said binding domain comprising SEQ ID NO: 1, 2, 3, 4, 5 and 6 or 7. The disclosure also extends to pharmaceutical compositions comprising said antibody molecules and use of the antibody molecules/compositions in treatment.

公开(公告)号：US11807680B2

公开(公告)日：2023-11-07

申请号：US17172109

申请日：2021-02-10

Applicant: UCB BIOPHARMA SRL

Inventor： Neesha Dedi ,  Breda Twomey ,  Michael John Wright ,  Gareth Charles Glyndwr Davies ,  David James McMillan

IPC: C07K16/22 ,  A61P9/12 ,  C07K14/51 ,  G01N33/68 ,  A61K39/00

CPC classification number: C07K16/22 ,  A61P9/12 ,  C07K14/51 ,  G01N33/6854 ,  A61K2039/505 ,  C07B2200/13 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/76

Abstract: This invention relates to crystals of the human Gremlin-1 protein, and the human Gremlin-1 protein in complex with an inhibitory antibody. The invention also relates to the structure of human Gremlin-1 (on its own, or in complex with the antibody) and uses of these structures in screening for agents which modulate Gremlin-1 activity. The invention further provides antibodies which bind an allosteric inhibitory site on Gremlin-1, together with pharmaceutical compositions and medical uses of such antibodies and agents identified by the screening methods.

公开(公告)号：US20230176071A1

公开(公告)日：2023-06-08

申请号：US17923904

申请日：2021-05-06

Applicant: UCB BIOPHARMA SRL

Inventor： Anastasios SPILIOTOPOULOS ,  David James MCMILLAN ,  Michael John Wright ,  Sebastian KELM ,  Xiaofeng LIU ,  Daniel John LIGHTWOOD

IPC: G01N33/68

CPC classification number: G01N33/6857

Abstract: A method of identifying of amino-acid residues on a target protein that form a binding site of a molecule of interest. Such method relies on selection of relevant patches of solvent-accessible residues and testing of an array of mutated proteins for changes of binding properties. Such method is useful for determining binding sites (epitopes) of antibodies, ligands and related molecules.

公开(公告)号：US10947304B2

公开(公告)日：2021-03-16

申请号：US16470996

申请日：2017-12-19

Applicant: UCB BIOPHARMA SRL

Inventor： Neesha Dedi ,  Breda Twomey ,  Michael John Wright ,  Gareth Davies ,  David James McMillan

IPC: C07K16/22 ,  A61P9/12 ,  C07K14/51 ,  G01N33/68 ,  A61K39/00

Abstract: This invention relates to crystals of the human Gremlin-1 protein, and the human Gremlin-1 protein in complex with an inhibitory antibody. The invention also relates to the structure of human Gremlin-1 (on its own, or in complex with the antibody) and uses of these structures in screening for agents which modulate Gremlin-1 activity. The invention further provides antibodies which bind an allosteric inhibitory site on Gremlin-1, together with pharmaceutical compositions and medical uses of such antibodies and agents identified by the screening methods.

公开(公告)号：US11261252B2

公开(公告)日：2022-03-01

申请号：US16513002

申请日：2019-07-16

Applicant: UCB BIOPHARMA SRL

Inventor： Helene Margaret Finney ,  Stephen Edward Rapecki ,  Michael John Wright ,  Kerry Louise Tyson

IPC: C07K16/28 ,  C07K16/18 ,  A61K39/00

Abstract: The present disclosure relates to multispecific molecule comprising a binding domain specific to the antigen CD22 and a binding domain specific to the antigen CD79a and/or CD79b, compositions comprising the same and use of both in treatment, for example the treatment of autoimmune disease.